UBS Group
ENTA icon

UBS Group’s Enanta Pharmaceuticals ENTA Stock Holding History

UBS Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,100
Closed -$158K – 8947
2014
Q4 		$158K Buy
+3,100
New +$139K ﹤0.01% 5261

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's ENTA Position: Q2 2026 in Review

UBS Group increased its Enanta Pharmaceuticals (ENTA) stake by 0.81% in Q2 2026, buying an estimated $6.92K and bringing the position to 64,319 shares worth $938K. The position accounts for ﹤0.01% of the portfolio, ranked #5785.

UBS Group first reported a position in ENTA in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.02M in Q4 2021. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • UBS Group held 64,319 shares of Enanta Pharmaceuticals worth $938K as of Q2 2026.
  • UBS Group bought 515 Enanta Pharmaceuticals shares in Q2 2026, an estimated $6.92K.
  • Enanta Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5785 holding.
  • UBS Group first reported a position in Enanta Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Enanta Pharmaceuticals position peaked at $3.02M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.